CureVac N.V. Ordinary Shares

CVAC XNAS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

Short interest (Dec 31)

0.2%

Net Short (Jan 05 ): 0.0%

Borrow Fee

7.88%

Available Shares

Price Chart

Company Overview

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Company Info

Exchange: NASDAQ

CIK: 0001809122

Asset Type: CS

Market Data

Market Cap: $1,049,305,010

Employees: 1,088

Status: Active

Short Interest

Current Borrow Fee 7.88%

Range: 7.88% - 7.88%

Available Shares 0

Range: 0 - 0

Recent Changes

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime